Intercept EASL data continue to fuel investor concerns

Additional data presented Thursday at EASL for Intercept's Ocaliva obeticholic acid (OCA) to treat NASH address some lingering efficacy questions from physicians, but safety signals and Intercept’s latest analysis methods continue to spook investors as the company's shares fell $15.93 (13%) to $104.75.

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) reported in February that Ocaliva

Read the full 511 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE